Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1996 1
1999 2
2000 4
2001 4
2002 3
2003 3
2004 4
2005 5
2006 6
2007 6
2008 3
2009 8
2010 4
2011 4
2012 6
2013 3
2014 5
2015 11
2016 12
2017 12
2018 16
2019 9
2020 11
2021 17
2022 9
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
Cazelles C, Belhadj K, Vellemans H, Camus V, Poullot E, Gaulard P, Veresezan L, Itti E, Becker S, Carvalho M, Dupuis J, Le Bras F, Lemonnier F, Roulin L, El Gnaoui T, Jardin F, Mounier N, Tilly H, Haioun C. Cazelles C, et al. Among authors: itti e. Leuk Lymphoma. 2021 Sep;62(9):2161-2168. doi: 10.1080/10428194.2021.1901090. Epub 2021 Mar 25. Leuk Lymphoma. 2021. PMID: 33764240
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Vilgrain V, et al. Among authors: itti e. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
Whole-Body Functional MRI and PET/MRI in Multiple Myeloma.
Mulé S, Reizine E, Blanc-Durand P, Baranes L, Zerbib P, Burns R, Nouri R, Itti E, Luciani A. Mulé S, et al. Among authors: itti e. Cancers (Basel). 2020 Oct 27;12(11):3155. doi: 10.3390/cancers12113155. Cancers (Basel). 2020. PMID: 33121132 Free PMC article. Review.
FDG PET/CT imaging as a biomarker in lymphoma.
Meignan M, Itti E, Gallamini A, Younes A. Meignan M, et al. Among authors: itti e. Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):623-33. doi: 10.1007/s00259-014-2973-6. Epub 2015 Jan 9. Eur J Nucl Med Mol Imaging. 2015. PMID: 25573631 Review.
Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis.
Bézard M, Kharoubi M, Galat A, Le Bras F, Poullot E, Molinier-Frenkel V, Fanen P, Funalot B, Moktefi A, Abulizi M, Deux JF, Lemonnier F, Guendouz S, Chalard C, Zaroui A, Itti E, Hittinger L, Teiger E, Oghina S, Damy T. Bézard M, et al. Among authors: itti e. Mayo Clin Proc. 2023 Jan;98(1):48-59. doi: 10.1016/j.mayocp.2022.08.016. Epub 2022 Dec 2. Mayo Clin Proc. 2023. PMID: 36464537
Lymph node imaging: basic principles.
Luciani A, Itti E, Rahmouni A, Meignan M, Clement O. Luciani A, et al. Among authors: itti e. Eur J Radiol. 2006 Jun;58(3):338-44. doi: 10.1016/j.ejrad.2005.12.038. Epub 2006 Feb 13. Eur J Radiol. 2006. PMID: 16473489 Review.
Whole-body diffusion-weighted imaging in lymphoma.
Lin C, Itti E, Luciani A, Haioun C, Meignan M, Rahmouni A. Lin C, et al. Among authors: itti e. Cancer Imaging. 2010 Oct 4;10 Spec no A(1A):S172-8. doi: 10.1102/1470-7330.2010.9029. Cancer Imaging. 2010. PMID: 20880782 Free PMC article. Review.
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Houot R, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Duléry R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Gutierrez FL, Menard C, Tarte K, Delfau MH, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F. Houot R, et al. Among authors: itti e. Nat Med. 2023 Oct;29(10):2593-2601. doi: 10.1038/s41591-023-02572-5. Epub 2023 Sep 14. Nat Med. 2023. PMID: 37710005 Free PMC article. Clinical Trial.
154 results